^
    Back
    Association details:
    Biomarker:SORT1 positive
    Cancer:Triple Negative Breast Cancer
    Drug:sudocetaxel zendusortide (TH 1902) (Tubulin polymerization promoter, Microtubule stabilizer, Sortilin inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    AACR 2023
    Title:

    4493 / 18 - Sudocetaxel Zendusortide (TH1902), a peptide-drug conjugate for the treatment of sortilin-positive (SORT1+) TNBC and Her2-positive breast cancers

    Published date:
    03/15/2023
    Excerpt:
    ...these preclinical data demonstrate the high anticancer properties of TH1902 against SORT1+ TNBC and Herceptin resistant Her2+ breast cancers.
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Sci
    Title:

    TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer

    Published date:
    08/12/2021
    Excerpt:
    By exploiting SORT1 function in ligand internalization, a new anticancer treatment strategy was designed to target SORT1-positive TNBC-derived cells both in vitro and in two in vivo tumor xenografts models....the docetaxel-TH19P01 conjugate (TH1902) exerted potent antiproliferative and antimigratory activities when tested on TNBC-derived MDA-MB-231 cells....This property allows for selective treatment of SORT1-positive TNBC and makes TH1902 a promising avenue for personalized therapy...
    DOI:
    10.1111/cas.15086